China Biologic Products Holdings Inc (CBPO) - Financial and Strategic SWOT Analysis Review

Region:Asia

Author(s):

Product Code:GDPH185322FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

June 2019

Total pages

69

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

China Biologic Products Holdings Inc (CBPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.

- Corporate strategy - Analyst's summarization of the company's business strategy.

- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history - Progression of key events associated with the company.

- Major products and services - A list of major products, services and brands of the company.

- Key competitors - A list of key competitors to the company.

- Key employees - A list of the key executives of the company.

- Executive biographies - A brief summary of the executives' employment history.

- Key operational heads - A list of personnel heading key departments/functions.

- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities - A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

China Biologic Product Holdings Inc (China Biologic) is a biopharmaceutical company that focuses on research and development, production, commercialization of plasma based products. Its products are used for prevention and treatment of life-threatening diseases, immune-deficiency related diseases and during medical emergencies. Its plasma products include human immunoglobulin, human albumin, human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, and human coagulation factor VIII. China Biologic's other product includes placenta polypeptide. It offers products to hospitals and other healthcare facilities in China.

China Biologic Products Holdings Inc Key Recent Developments

May 10,2019 China Biologic reports financial results for the first quarter of 2019

Mar 06,2019 China Biologic reports financial results for the fourth quarter and fiscal year 2018

Jan 07,2019 China Biologic Reiterates Full Year 2018 Financial Forecast

Dec 14,2018 China Biologic announces dismissal of lawsuit filed in Cayman Islands by former chairman

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

China Biologic Products Holdings Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Beijing Beilu Pharmaceutical Co Ltd

Boya Bio-Pharmaceutical Group Co., Ltd

China National Biotec Group

Shanghai RAAS Blood Products Co., Ltd.

Shenzhen Weiguang Biological Products Co., Ltd.

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

China Biologic Products Holdings Inc - Key Facts

China Biologic Products Holdings Inc - Key Employees

China Biologic Products Holdings Inc - Key Employee Biographies

China Biologic Products Holdings Inc - Major Products and Services

China Biologic Products Holdings Inc - History

China Biologic Products Holdings Inc - Company Statement

China Biologic Products Holdings Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 - Company Analysis

Company Overview

China Biologic Products Holdings Inc - Business Description

Business Segment: Biomaterial Products

Overview

Performance

Business Segment: Biopharmaceutical Segment

Overview

Performance

R&D Overview

China Biologic Products Holdings Inc - Corporate Strategy

China Biologic Products Holdings Inc - SWOT Analysis

SWOT Analysis - Overview

China Biologic Products Holdings Inc - Strengths

China Biologic Products Holdings Inc - Weaknesses

China Biologic Products Holdings Inc - Opportunities

China Biologic Products Holdings Inc - Threats

China Biologic Products Holdings Inc - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 - Company's Lifesciences Financial Deals and Alliances

China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

China Biologic Products Holdings Inc, Recent Deals Summary

Section 5 - Company's Recent Developments

May 10, 2019: China Biologic reports financial results for the first quarter of 2019

Mar 06, 2019: China Biologic reports financial results for the fourth quarter and fiscal year 2018

Jan 07, 2019: China Biologic Reiterates Full Year 2018 Financial Forecast

Dec 14, 2018: China Biologic announces dismissal of lawsuit filed in Cayman Islands by former chairman

Nov 01, 2018: China Biologic reports financial results for the third quarter of 2018

Aug 28, 2018: China Biologic responds to lawsuit filed in Cayman Islands by former Chairman

Aug 13, 2018: China Biologic names Bing Li as new CEO

Aug 03, 2018: China Biologic reports financial results for the second quarter of 2018

May 04, 2018: China Biologic Reports Financial Results For First Quarter Of 2018

May 04, 2018: China Biologic Announces First Quarter 2018 Financial Results

Section 6 - Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List of Figure

List of Figures

China Biologic Products Holdings Inc, Performance Chart (2014 - 2018)

China Biologic Products Holdings Inc, Ratio Charts

China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List of Table

List of Tables

China Biologic Products Holdings Inc, Key Facts

China Biologic Products Holdings Inc, Key Employees

China Biologic Products Holdings Inc, Key Employee Biographies

China Biologic Products Holdings Inc, Major Products and Services

China Biologic Products Holdings Inc, History

China Biologic Products Holdings Inc, Subsidiaries

China Biologic Products Holdings Inc, Key Competitors

China Biologic Products Holdings Inc, Ratios based on current share price

China Biologic Products Holdings Inc, Annual Ratios

China Biologic Products Holdings Inc, Annual Ratios (Cont...1)

China Biologic Products Holdings Inc, Annual Ratios (Cont...2)

China Biologic Products Holdings Inc, Interim Ratios

China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

China Biologic Products Holdings Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022